Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4121 - Use and effectiveness of adjuvant ovarian function suppression (OFS) in premenopausal women with early breast cancer.


11 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Breast Cancer


Arlindo Ferreira


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


A.R. Ferreira1, J. Ribeiro2, A. Mayer3, M. Brito4, A. Miranda3, J.P. Fernandes5, J.L. Passos-Coelho6, L. Costa1, I. Vaz-Luís7

Author affiliations

  • 1 Medical Oncology, Hospital de Santa Maria and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-035 - Lisbon/PT
  • 2 Medical Oncology, Fundação Champalimaud, 1400-038 - Lisbon/PT
  • 3 Registo Oncológico Regional Do Sul, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 - Lisbon/PT
  • 4 Medical Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 - Lisbon/PT
  • 5 Medical Oncology, Hospitais CUF Lisboa, 1998-018 - Lisbon/PT
  • 6 Medical Oncology, Hospital da Luz and Hospital de Beatriz Ângelo, 1500-650 - Lisbon/PT
  • 7 Department Of Medicine And Unit Inserm 981, Institut Gustave Roussy, 94800 - Villejuif/FR


Abstract 4121


OFS either in association with tamoxifen (TAM) or an aromatase inhibitor (AI) improved disease-free survival in young women (≤35) and in those premenopausal women at higher risk of recurrence. However, its survival benefit remains largely unknown. In this study we characterize real-world use of adjuvant OFS from 2006 to 2015 and analyze its overall survival (OS) impact.


Retrospective observational cohort study of premenopausal women with Stage I-III hormone receptor-positive (HR+) breast cancer treated at one of 5 large centers in Portugal and diagnosed from 2006-2015. Study outcomes were use of OFS and OS. Pearson’s Chi2 test, logistic regression and Cox proportional hazards models were used.


Of 1717 eligible patients, 304 (17.3%) were treated with adjuvant OFS, of which 271 (15.4%) in combination with TAM and 33 (1.9%) with AI. Baseline characteristics differed by subgroups: patients treated with OFS were younger, had larger, less differentiated (grade III 16% vs 24% for OFS), more frequently HER2 positive (14% vs. 19% for OFS) tumors, and underwent more frequently mastectomy (48% vs 57% for OFS), radiotherapy (25% vs 31% for OFS) and (neo)adjuvant chemotherapy (73% vs 79% for OFS). Adjuvant OFS was used at least since 2006 with an increase in its use from 2014 onward (16% vs 25% since 2014), particularly for the combination with AI (0.4% vs 8% since 2014). In a multivariate model, characteristics associated with use of OFS included younger age and year of diagnosis ≥2014 (both p 


In the real-world setting, a quarter of premenopausal women with early breast cancer were already treated with adjuvant OFS in 2014. After a median follow-up of 3 years, adjuvant OFS showed an OS benefit.

Clinical trial identification

Not applicable.

Legal entity responsible for the study

Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.